Version 1
: Received: 23 February 2024 / Approved: 23 February 2024 / Online: 23 February 2024 (09:37:56 CET)
How to cite:
Papalexis, N.; Peta, G.; Marinelli, A.; Errani, C.; Quarchioni, S.; Di Carlo, M.; Miceli, M.; Facchini, G. Efficacy and Safety of Arterial Embolization for Scapular Metastases. Preprints2024, 2024021359. https://doi.org/10.20944/preprints202402.1359.v1
Papalexis, N.; Peta, G.; Marinelli, A.; Errani, C.; Quarchioni, S.; Di Carlo, M.; Miceli, M.; Facchini, G. Efficacy and Safety of Arterial Embolization for Scapular Metastases. Preprints 2024, 2024021359. https://doi.org/10.20944/preprints202402.1359.v1
Papalexis, N.; Peta, G.; Marinelli, A.; Errani, C.; Quarchioni, S.; Di Carlo, M.; Miceli, M.; Facchini, G. Efficacy and Safety of Arterial Embolization for Scapular Metastases. Preprints2024, 2024021359. https://doi.org/10.20944/preprints202402.1359.v1
APA Style
Papalexis, N., Peta, G., Marinelli, A., Errani, C., Quarchioni, S., Di Carlo, M., Miceli, M., & Facchini, G. (2024). Efficacy and Safety of Arterial Embolization for Scapular Metastases. Preprints. https://doi.org/10.20944/preprints202402.1359.v1
Chicago/Turabian Style
Papalexis, N., Marco Miceli and Giancarlo Facchini. 2024 "Efficacy and Safety of Arterial Embolization for Scapular Metastases" Preprints. https://doi.org/10.20944/preprints202402.1359.v1
Abstract
Background: To investigate the safety and efficacy of palliative arterial embolization for metastases of the scapula.
Materials and Methods: We studied the files of the patients who underwent palliatrive arterial embolization for metastases of the scapula from January 2016 to January 2023, 15 patients (8 M, and 7 F) with a mean age of 62 years (SD 10.2) with two patients receiving a second procedure, for a total of 17 embolizations. Data on technical and clinical success, as well as changes in tumor size, were collected. All embolization-related complications were evaluated according to the CIRSE classification system for complications.
Results: The average follow-up was 18 months (Range 6-36 months). The main primary tumor were renal, lung and breast cancer. The primary arteries embolized were the circumflex scapular artery, the dorsal scapular artery, and the thoracoacromial trunk. A mixture of Glubran and Lipiodol in a 1:2 ratio was used for embolization, with an average of 1.1 mL (Range 0.5-1.5 mL) used per procedure. The efficacy of embolization was measured using the Visual Analogue Scale (VAS), with values recorded at baseline, at 1, 3, 6, and 12 months post-embolization, and at 6-month intervals after. Baseline VAS scores averaged 7.2 (SD 1.5), decreasing to 2.8 (SD 0.9) at one month. Progressive reduction was observed at 3, 6, and 12 months with scores of 2.3 (SD 0.8), 1.9 (SD 0.7), and 1.6 (SD 0.6) respectively. Metastatic tumor size was reduced from a mean of 192.2 cm3 (range 38.7 to 480.1 cm3) pre-embolization to a mean of 177.3 cm3 (range 37.2 to 455.5 cm3) at the 12-month follow-up (p
Keywords
Radiology; Interventional; Bone neoplasms; Metastases; Embolization; Therapeutic; Oncology
Subject
Public Health and Healthcare, Public Health and Health Services
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
